tapebrief

LDOS · Q4 2025 Earnings

Cautious

Leidos

Reported February 17, 2026

30-second summary

Q4 revenue fell 4% YoY to $4.21B as the six-week government shutdown compressed the quarter, but FY25 still landed at $17.17B (+3%) with non-GAAP EPS of $11.99 — $0.24 above the high end of the raised guide — and adjusted EBITDA margin of 14.1% (Q4 alone 13.2%). FY26 guidance is the tell: revenue $17.5–17.9B (up to 4% growth), EPS $12.05–12.45 (midpoint $12.25, roughly flat to FY25 actual), EBITDA margin stepped back to "mid 13s" from FY25's 14.1% print — a ~60bps step-down — with management explicitly framing growth as back-loaded toward "approaching double digits" exiting the year. After two consecutive quarters of raises, the algorithm has flattened — the question for 2026 is whether the H2 acceleration management is promising materializes from the $7B of Q4-slipped awards, $20B pending pipeline, and 1.3 book-to-bill, or whether the ~60bps mid-13s margin step-down is the leading indicator.

Headline numbers

EPS

Q4 FY2025

$2.76

Revenue

Q4 FY2025

$4.21B

-4.0% YoY

Gross margin

Q4 FY2025

17.6%

Free cash flow

Q4 FY2025

$0.45B

Operating margin

Q4 FY2025

11.2%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$4.21B-4.0%$4.47B-5.9%
EPS$2.76$3.05-9.5%
Gross margin17.6%18.4%-80bps
Operating margin11.2%12.0%-80bps
Free cash flow$0.45B$0.68B-33.5%

Guidance

Strong FY2025 beats on EPS and EBITDA margin; FY2026 guidance is conservative with flat-to-low-single-digit EPS growth but improved operating cash flow, signaling a deceleration cycle after raised 2025 results.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueFY2025$17.00 - $17.25 billion$17.174 billion+0.024 billion above midpoint; within rangeBeat
Non-GAAP Diluted EPSFY2025$11.45 - $11.75$11.99+$0.24 above high endBeat
Adjusted EBITDA MarginFY2025High 13%13.2%+~20bps above high-13s guidanceBeat

New guidance

MetricPeriodGuideYoY
RevenueFY2026$17.5 - $17.9 billion+1.8-4.2% YoY
Non-GAAP Diluted EPSFY2026$12.05 - $12.45+0.5-3.8% YoY
Adjusted EBITDA MarginFY2026Mid 13%
Cash Flows Provided by Operating ActivitiesFY2026Approximately $1.75 billion+6.1% YoY

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
National Security & Digital$1.846B-3.0%
Health & Civil$1.205B-9.0%
Commercial & International$0.61B+1.0%
Defense Systems$0.546B+1.0%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Adjusted EBITDA$556 million
Adjusted EBITDA Margin13.2%
Net Bookings$5.6 billion
Book-to-Bill Ratio1.3
Total Backlog$49.0 billion
Funded Backlog$9.7 billion
Operating Cash Flow$495 million
Free Cash Flow Conversion127%

Management tone

Narrative arc: DOGE freeze (Q1) → logjam breaking up (Q2) → awards in the numbers (Q3) → execution mode with tripled capex (Q4).

The shift from Q3 to Q4 is from "thriving through adversity" to "redefining what it means to be a national security company" — a frame that has migrated from operational to transformational. Bell's anchor line — "We are now firmly in strategy execution mode for our North Star 2030 strategy with a strong bias for velocity and a strong productive sense of urgency" — pairs with the announcement that capex is tripling to $350M, that two leadership changes were made, and that "co-investment opportunities with this administration around critical war fighting and national needs" are being negotiated. This is markedly more aggressive than the August "logjam breaking up" framing or the November "awards picking up." The question is whether this aggression is being matched by 2026 guidance — and the answer is no, which is the dissonance worth pricing.

The margin narrative has shifted from "incremental improvement" to "fundamental business model change." Bell's claim that "Our margin expansion journey has meaningfully changed how we view what is possible, and that change permeates the entire company" with "six consecutive quarters of positive net EACs" is the most confident margin framing the company has offered. But the FY26 guide steps margin back ~60bps to mid-13s from the 14.1% print of FY25 — meaning the cultural confidence is not being underwritten by the numerical guide. Either the guide is sandbagged or the narrative is ahead of the reality; investors should not assume both can be true.

The capital allocation pivot is more aggressive than any prior quarter. Q2 framed M&A as "now part of the playbook"; Q3 added the KUDU deal with $400M in cross-pipeline opportunities; Q4 announces tripled capex, the Entrust energy acquisition, no buybacks in the 2026 guide, and 2.6x pro-forma leverage. Bell's framing — "organic and inorganic investments will become more prevalent in our capital management strategy" — is a clean shift away from the buyback-and-dividend posture of 2024. Investors modeling 2026 EPS off historical share-count attrition should mark to no buybacks as the base case.

Administration alignment language has notably retreated. Prior calls leaned heavily on "alignment with the priorities of the administration"; this quarter's prepared commentary is more muted on that frame, even as capex tripling and "co-investment opportunities" suggest the alignment is operationally deeper. This is either deliberate downplay to manage political-risk optics or an acknowledgment that the policy-to-bookings conversion is taking longer than the Q2 thaw narrative implied. Either reading argues for more scrutiny on named task orders, not less.

The risks management itemized — six-week shutdown impact on Q4, managed health headwinds before inflection, airborne programs margin ebb, fixed-price homeland execution risk, $90M Section 174 cash headwind — are more specific and more numerous than in any prior call this year. The specificity is healthy disclosure; the volume is the tone signal. When management lists five named risks in a forward outlook, the implicit framing is that the year requires more execution discipline than the headline guide suggests.

Recurring themes management leaned on this quarter:

North Star 2030 strategy execution acceleration and organizational alignmentAdministration alignment driving demand across defense tech, cyber, and homeland prioritiesMargin expansion as systemic cultural and operational achievementPortfolio optimization: divest legacy, acquire growth pillars (Kudu cyber, And Trust energy)Velocity bias and productive urgency in capital deployment and innovationIntegrated hardware-software solutions as competitive differentiator

Risks management surfaced:

Government shutdown impacts (six-week shutdown in 2025 compressed Q4 revenue)Managed health services business headwinds in near term before inflectionAirborne programs margin ebb in defense segment during 2026Fixed-price work exposure in homeland segment requiring execution disciplineSection 174 tax timing headwind reducing 2026 free cash flow by $90M

Q&A highlights

Seth Seethman · JP Morgan

What investment areas will receive additional capex, how does that support defense business ramp, and what is the relationship to co-investment opportunities with the Department of War? Also, how should we model the early-year weakness given the guidance for stronger growth exiting the year?

Leidos is investing in co-development opportunities with DoD and FAA modernization, particularly in maritime growth, integrated air defense, and hypersonics. Lower growth expected in H1 2026 with acceleration in H2 driven by Golden Dome initiatives, FAA modernization catalysts, and new program ramp-ups. $7 billion in awards slipped from Q4 into Q1, with $20 billion pending awards and $49 billion backlog.

$7 billion in awards slipped from Q4 into current quarter$20 billion of pending awards$49 billion backlog1.3x book-to-bill ratio in Q3 and Q4

John Godden · Citi

Given strong book-to-bill performance without a dip, can you elaborate on expectations for award activity acceleration and the shape of that acceleration through the year?

Management attributes 1.3x book-to-bill to deliberate three-year investment in growth function and new leadership. Emphasizes robust pipeline, strong re-compete and takeaway win rates, and highest next-12-month pipeline submittal activity. Three-quarters of 2026 bid pipeline expected to target new business and takeaways versus re-competes.

1.3x book-to-bill in Q3 and Q4 result of purposeful growth function investmentHighest next-12-month pipeline submittal activity in Q475% of 2026 pipeline focused on new business and takeawaysStrong re-compete and takeaway win rates

Gautam Khanna · TD Cowan

What are expectations for VA medical exam recompete terms and timing, and what is Leidos doing to sustain profitability given typical margin pressure in recompetes?

Leidos maintains commitment to health business despite entry of fourth vendor and potential work-share reallocation. Growth focuses are rural health transformation and behavioral/integrated health. VA medical disability exam RFP expected mid-2026. Management expects to sharpen pencil while maintaining profitability, with health business projected to achieve above 20% margins beyond 2026.

RFP and bid expected in summer 2026 for medical disability examsHealth business projected at robust profitability above 20% beyond 2026Reduced veteran exam backlog by almost 60%Investment focus on cost reduction, volume increase, and efficiency improvements

Colin Canfield · Cantor

Where is the greatest conservatism in 2026 guidance, what key milestones could trigger upside, and how should we bridge 2026 outperformance into 2027 expectations?

Greatest conservatism in defense segment upside (if DoD funding decisions, Golden Dome, maritime accelerate) and FAA opportunities (if customer decisions pull forward). Health margin conservatism built in around potential volume reallocation. No one-time items included in guidance; momentum from 2026 outperformance expected to carry into 2027.

No one-time items in 2026 guidanceDefense segment potential upside if Golden Dome and maritime accelerateFAA upside if customer funding decisions pull forwardHealth margin built conservatively for potential volume changes

Ken Herbert · RBC Capital Markets

How are you thinking about capital allocation, incremental M&A opportunities, and buyback expectations given 2.6x pro forma leverage after Entrust?

Management prioritizes organic and inorganic investments aligned with North Star 2030 strategy. No buybacks assumed in 2026 guidance; capital will focus on growth pillars and Entrust integration. Dividend program continues, with opportunistic shareholder-friendly deployments evaluated. Will maintain rigorous ROI analysis on all capital deployment.

Pro forma leverage ~2.6x after EntrustNo share repurchases in 2026 guidanceOrganic and inorganic investments are capital deployment prioritiesDividend program continues

Answers to last quarter's watch list

Q4 revenue print against the held $17.00–17.25B FY range. FY25 closed at $17.17B — comfortably within the held range, near the midpoint. Q4 itself printed $4.21B (-4% YoY), below the implied $4.32–4.57B Q4 range Q3 math suggested, but the FY held because of Q3 strength. Management's "absorb 3% top-line hits" cushion was real at the FY level; the Q4 print itself shows the six-week shutdown cost roughly the difference between the held FY range and the lower implied Q4. Status: Resolved positively.
Operating cash flow Q4 finish to $1.65B. FY25 operating cash flow finished at $1.75B — ~$100M above the ~$1.65B guide (Cage: "outperforming our cash flow guidance by $100 million"). FY25 free cash flow was $1.63B. Q4 OCF of $495M (a record fourth-quarter print) carried the cash story across the line. The shutdown-induced collection-delay risk Bell flagged in Q3 did not materialize. Status: Resolved positively.
Defense Systems margin progression toward sustainable double-digits. The company did not break out segment margins in the press release detail provided, and Defense Systems revenue growth itself decelerated sharply to +1% from Q3's +11.5%. Management's FY26 commentary — a modest decline in Defense margins as some high-margin airborne programs ebb — is the relevant forward signal and points in the opposite direction from sustainable double-digit progression near term. Status: Continue monitoring.
Named OBBB / Golden Dome task-order awards. Bell referenced Golden Dome and maritime as upside catalysts and mentioned $7B in slipped Q4 awards plus a $20B pending pipeline, but the press release and Q&A did not itemize specific OBBB-attributed task-order wins by name. The bookings strength (1.3 book-to-bill) is consistent with the thesis; the absence of named awards means the addressable framing remains directional rather than booked. Status: Continue monitoring.
2026 organic growth framing. FY26 revenue guidance of $17.5–17.9B (+1.8% to +4.2% YoY) is below the mid-single-digit organic growth bar Q3 Q&A teed up, with management explicitly framing the shape as back-loaded toward "approaching double digits" exit velocity. The headline guide undershoots the Q3 trajectory expectation; the qualitative exit-velocity frame is the offsetting bullish piece, but exit velocity is not bookable for FY26 reported revenue. Status: Resolved negatively on the headline frame; the exit-velocity claim becomes a new watch item.
Health & Civil end-2026 recompete shaping. Bell confirmed RFP expected mid-2026 with bid in summer 2026; growth focus shifts to rural health and behavioral/integrated health; veteran exam backlog cut by ~60%; above-20% margins expected beyond 2026. Q4 H&C revenue printed -9% YoY — the sharpest segment reversal — which management attributes to managed health services headwinds and shutdown timing, with inflection expected. Status: Continue monitoring — competitive positioning is being disclosed but the segment's near-term trajectory worsened.

What to watch into next quarter

Conversion of the $7B Q4-slipped awards in Q1. Management told analysts the slippage was timing, not demand-loss. Watch for a Q1 book-to-bill print and named definitizations — Q1 needs to show the slipped awards landing, otherwise the H2 acceleration thesis loses its leading indicator.

Defense Systems revenue trajectory after the +1% Q4 print. Seven consecutive quarters of HSD-LDD growth ended this quarter. Watch whether Q1 reaccelerates or whether the airborne-margin-ebb commentary signals a broader Defense Systems pause. A second sub-mid-single-digit quarter would meaningfully damage the segment-mix thesis.

H&C inflection timing. Q4 printed -9%. Management frames the headwinds as near-term with inflection ahead. Watch for the specific quarter management points to for the inflection — and whether Q1/Q2 prints show sequential improvement toward positive YoY, or whether the segment requires the full year to recover.

Entrust close and post-close guidance update. Management explicitly excluded Entrust from FY26 guidance, with a planned post-close update in Q2. Watch the size of the guidance lift versus what sell-side has triangulated from the deal disclosure — under-delivery against expectations would imply the underlying organic guide was tighter than the headline suggested.

Margin walk from 14.1% FY25 actual to mid-13s FY26 guide. The ~60bps step-back is the cleanest "hidden cut" in the print. Watch Q1 and Q2 EBITDA margin prints — if margin holds in the high-13s through H1, the FY26 guide is sandbagged; if margin compresses toward mid-13s in H1, the guide is realistic and the FY25 exit rate was the peak.

EPS leverage at H2 revenue acceleration. The FY26 EPS midpoint of $12.25 is essentially flat against FY25's $11.99 despite revenue growth and no buybacks. Watch whether H2 EPS leverage materializes proportionate to the promised "approaching double digits" revenue exit — if it doesn't, the operating leverage story that anchored FY25's beats is structurally weakening.

Sources

  1. Leidos Q4 2025 Press Release — https://www.sec.gov/Archives/edgar/data/1336920/000133692026000028/ldos1022026ex991.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.